Simulations Plus Reports Q3 2025: Revenue Grows 10% Amid Significant Net Loss and Impairments

Simulations Plus, Inc. (NASDAQ: SLP) - Q3 2025 Update

Simulations Plus continues to evolve with strong revenue growth but faces significant challenges reflected in its latest financial results. Below are key points from the company's recent financial statement for the quarter ending May 31, 2025:

Positive Aspects:

• Revenue Growth: Total revenues increased 10% to $20.4 million, up from $18.5 million in Q3 2024.
• Software Segment Growth: Software-related revenue rose by 6%, reaching $12.6 million, primarily driven by contributions from the Pro-ficiency acquisition.
• Service Revenue Expansion: Services revenue increased by 17% to $7.7 million, showcasing strong demand in consulting services.
• Cash Flow from Operations: Generated $12.5 million in net cash provided by operating activities despite a net loss.
• Sufficient Cash Reserves: As of May 31, 2025, the company had $27.0 million in cash and cash equivalents, indicating strong liquidity.

Negative Aspects:

• Net Loss: Reported a net loss of $67.3 million, a significant decline from a profit of $3.1 million in Q3 2024.
• Impairment Charges: Significant impairment charges of $77.2 million due to underperformance in certain segments.
• Increased Operating Expenses: Total operating expenses surged by 667% due to these impairment charges, totaling $87.3 million.
• Decline in Gross Margin: Gross margin decreased from 71% to 64%, affected by rising costs associated with software and services.
• Decreased Other Income: Other income fell by 91%, primarily due to diminished interest income linked to cash being utilized in acquisitions.

Key Statistics:

• Revenues: $20,363,000 (Q3 2025) vs. $18,544,000 (Q3 2024)
• Gross Profit: $13,032,000 (Q3 2025) vs. $13,257,000 (Q3 2024)
• Total Operating Expenses: $87,258,000 (Q3 2025) vs. $11,377,000 (Q3 2024)
• Net Income (Loss): $(67,317,000) (Q3 2025) vs. $3,137,000 (Q3 2024)
• Cash and Cash Equivalents: $26,950,000 (May 31, 2025)

Despite notable revenue increases, the challenges posed by impairments and increased expenses highlight the need for careful management as Simulations Plus continues to navigate the complexities of the biopharmaceutical industry.